Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lipids and chronic heart failure].

J Spinar1, L Spinarová, J Vítovec

  • 1II. interní klinika Fakultní nemocnice U sv. Anny, Brno.

Vnitrni Lekarstvi
|May 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial.

Bratislavske lekarske listy·2021
Same author

MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock.

Bratislavske lekarske listy·2018
Same author

Conservative versus invasive treatment in hypertrophic obstructive cardiomyopathy: an echocardiography study.

Bratislavske lekarske listy·2016
Same author

Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance.

Intensive care medicine·2015
Same author

Central pulse pressure and variability in matrix metalloproteinases genes and their inhibitors in patients with ischemic heart disease.

Physiological research·2015
Same author

[Contemporary view on liver impairment in heart failure].

Vnitrni lekarstvi·2013
Same journal

Pharmacological profile of mepolizumab.

Vnitrni lekarstvi·2023
Same journal

Atypical form of Goodpasture's disease.

Vnitrni lekarstvi·2023
Same journal

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.

Vnitrni lekarstvi·2023
Same journal

Dyslipidemia - the known unknown.

Vnitrni lekarstvi·2023
Same journal

Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!

Vnitrni lekarstvi·2023
Same journal

Implications of highly suppressive treatment HIV infection.

Vnitrni lekarstvi·2023
See all related articles

Chronic heart failure is increasingly caused by ischemic heart disease and hypertension. Statins significantly reduce mortality in heart failure patients, suggesting hypolipidemic therapy is crucial for managing this condition.

Area of Science:

  • Cardiology and cardiovascular disease research.
  • Pharmacological interventions for chronic conditions.
  • Epidemiology of heart failure in European populations.

Context:

  • Chronic heart failure (CHF) causes have shifted, with ischemic heart disease and hypertension now primary drivers in up to 90% of cases.
  • CHF prevalence in Europe is 0.4-2%, translating to a substantial patient burden in countries like the Czech Republic.
  • Current pharmacological CHF treatment relies on a combination of five drug classes, including ACE inhibitors.

Purpose:

  • To evaluate the impact of simvastatin on mortality in patients with ischemic heart disease, particularly those developing chronic heart failure.
  • To assess the role of hypolipidemic therapy in managing heart failure secondary to ischemic heart disease.
  • To examine hyperlipoproteinemia prevalence and management post-heart transplantation.

Related Experiment Videos

Summary:

  • The Scandinavian Simvastatin Survival Study (4S) involving 4,444 patients showed simvastatin reduced CHF incidence (8.3% vs. 10.3%) and mortality (47/184 vs. 73/228) in ischemic heart disease patients.
  • Simvastatin treatment led to a 19% relative risk reduction in mortality for heart failure patients, with a number needed to treat (NNT) of 15 over 5 years.
  • Hypolipidemic therapy, including statins, is recommended for heart failure patients with ischemic heart disease and is essential for managing hyperlipoproteinemia post-heart transplant.

Impact:

  • Findings support integrating hypolipidemic treatment, specifically statins, into standard care for heart failure patients with ischemic heart disease.
  • This study highlights the significant benefit of statins in reducing mortality, underscoring their importance in cardiovascular disease management.
  • The results inform treatment strategies for hyperlipoproteinemia in heart transplant recipients, emphasizing diet, medication adjustment, and statin therapy.